Jasper Therapeutics JSPR
NASDAQ JSPR
$0.51 +0.01 (+2.40%)
As of: Oct 21, 2026 · 9:40 AM EDT

Jasper Therapeutics (JSPR) Non-Current Debt (2022)

Updated

Jasper Therapeutics (JSPR) reported Non-Current Debt of -$183,876 for FY2019.

Analysis

Jasper Therapeutics (JSPR) Non-Current Debt (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Eli Lilly 1,140.41 Bn 1,108.99 Bn 19.71 Bn 47.86 Bn
2 Johnson & Johnson 618.57 Bn 537.10 Bn 17.26 Bn 37.34 Bn
3 AbbVie 509.95 Bn 483.06 Bn 12.70 Bn 62.48 Bn
4 Merck 366.63 Bn 321.01 Bn 12.21 Bn 51.08 Bn
5 Novartis Ag 298.47 Bn 262.46 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 263.21 Bn 236.89 Bn 12.86 Bn 23.68 Bn
7 Amgen 236.71 Bn 192.11 Bn 7.24 Bn 51.86 Bn
8 Gilead Sciences 193.05 Bn 167.25 Bn 6.22 Bn 23.83 Bn
9 Pfizer 171.45 Bn 118.10 Bn 10.94 Bn 60.50 Bn
10 Jasper Therapeutics 14.69 Mn -111.73 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 18,000.00
API Access

Jasper Therapeutics Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=JSPR&period=max&api_key=YOUR_API_KEY